Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Personalis, Inc. - Common Stock (NQ: PSNL )

3.600 -0.220 (-5.76%)
Streaming Delayed Price Updated: 3:50 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Personalis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 169 companies set new 52-week lows. 
Via Benzinga
Personalis to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
From Personalis, Inc.
Via Business Wire
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
Analyst Ratings for Personalis
Via Benzinga
Recap: Personalis Q1 Earnings
Via Benzinga
Personalis's Return On Capital Employed Insights
Via Benzinga
Personalis Reports Second Quarter 2023 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis to Participate at Upcoming Investor Conferences
From Personalis, Inc.
Via Business Wire
Personalis to Announce Second Quarter 2023 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis Files Second Patent Infringement Suit Against Foresight Diagnostics
From Personalis, Inc.
Via Business Wire
Earnings Outlook For Personalis
Via Benzinga
Dr. Kenneth J. Widder Joins Personalis Board of Directors
From Personalis, Inc.
Via Business Wire
Personalis Announces Two Abstracts Accepted for Presentation at ASCO 2023
From Personalis, Inc.
Via Business Wire
Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer
From Personalis, Inc.
Via Business Wire
Personalis Reports First Quarter 2023 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis, ABRCC, and Criterium Announce Major Prospective Clinical Trial for Residual and Recurrent Disease Detection in Triple Negative Breast Cancer
From Personalis, Inc.
Via Business Wire
Personalis to Announce First Quarter 2023 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis to Participate at the 22nd Annual Needham Virtual Healthcare Conference
From Personalis, Inc.
Via Business Wire
Personalis Joins Top UK Cancer Research Organizations to Evaluate Earlier Cancer Recurrence Detection Through Groundbreaking Study
From Personalis, Inc.
Via Business Wire
Personalis Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting 2023
From Personalis, Inc.
Via Business Wire
Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay
From Personalis, Inc.
Via Business Wire
Personalis Appoints Christopher Hall as Chief Executive Officer
From Personalis, Inc.
Via Business Wire
Toll Brothers To Rally 25%? Here Are 10 Other Analyst Forecasts For Friday
Oppenheimer boosted the price target for Universal Display Corporation (NASDAQ: OLED) from $150 to $160. Oppenheimer analyst Martin Yang maintained an Outperform rating on the stock. Universal Display... 
Via Benzinga
Personalis Reports Fourth Quarter and Full Year 2022 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis to Announce Fourth Quarter and Full Year 2022 Financial Results
From Personalis, Inc.
Via Business Wire
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
Personalis to Participate at Upcoming Investor Conferences
From Personalis, Inc.
Via Business Wire
Analyst Upgrades Personalis; Says Biopharma Is Strong, Cash Burn Is Down
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 6, 2023
Via Benzinga
Why Personalis Shares Are Trading Higher Today
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.